You are here

  • Home
  • Archive
  • Volume 14, Issue 4
  • Rofecoxib increased risk of CV events in patients with history of colorectal adenomas ⩾1 year after stopping treatmentRofecoxib increased risk of CV events in patients with history of colorectal adenomas ⩾1 year after stopping treatment

Article Text

Article menu
Download PDFPDF
Therapeutics
Rofecoxib increased risk of CV events in patients with history of colorectal adenomas ⩾1 year after stopping treatment

https://doi.org/10.1136/ebm.14.4.111

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    STUDY DESIGN

    Design:

    randomised controlled trial (RCT) (The Adenomatous Polyp Prevention on Vioxx [APPROVe] study). ClinicalTrials.gov NCT0282386.

    Allocation:

    unclear.*

    Blinding:

    blinded (patients, clinicians, and outcome assessors).*

    STUDY QUESTION

    Setting:

    108 centres worldwide.

    Patients:

    2587 patients ⩾40 years of age (mean age 59 y, 62% men) who had ⩾1 histologically confirmed large bowel adenoma removed in the 12 weeks before study entry and no known remaining polyps in the bowel after complete colonoscopy. Exclusion criteria included need for chronic non-steroidal anti-inflammatory drug treatment; uncontrolled hypertension (>165/95 mm Hg); angina or congestive heart failure; myocardial infarction (MI), coronary angioplasty, or coronary arterial bypass grafting in the past year; and …

    View Full Text

    Footnotes

    • Source of funding: Merck Research Laboratories.